<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0712222984
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE JAZEERA 40 mg/ml Lyophilisate For solution For infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GEMCITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="THYMOORGAN PHARMAZIE GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            THYMOORGAN PHARMAZIE GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gemcitabine Jazeera belongs to a group of medicines called &ldquo;cytotoxics&rdquo;. These medicines kill dividing cells, including cancer cells.<br />Gemcitabine Jazeera may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer you have.<br />Gemcitabine Jazeera is used in the treatment of a number of types of cancer including:</p><ul><li>Non-small cell lung cancer (NSCLC), alone or together with cisplatin</li><li>Pancreatic cancer</li><li>Breast cancer, together with paclitaxel</li><li>Ovarian cancer, together with carboplatin</li><li>Bladder cancer, together with cisplatin</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given Gemcitabine Jazeera</strong></p><ul><li>If you are allergic to gemcitabine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are breast-feeding.</li></ul><p>Tell the doctor if you think any of the above applies to you.</p><p><strong>Warnings and precautions</strong><br />Before the first infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function. Before each infusion you will also have samples of your blood taken to check if you have enough blood cells to receive Gemcitabine Jazeera. Your doctor may decide to change your dose or delay treating you, depending on your general condition and if your blood cell counts are too low.</p><p>Periodically you will have samples of your blood taken to check your kidney and liver function.</p><p><em>Talk to your doctor, pharmacist or nurse before using Gemcitabine Jazeera:</em></p><p>If you have, or have previously had liver disease, heart disease, vascular disease or problems with your kidneys talk to your doctor or hospital pharmacist as you may not be able to receive Gemcitabine Jazeera.</p><p>If you have recently had, or are going to have radiotherapy, please tell your doctor as there may be an early or late radiation reaction with Gemcitabine Jazeera.</p><p>If you have been vaccinated recently, please tell your doctor as this can possibly cause bad effects with Gemcitabine Jazeera.</p><p>If during treatment with this medicine, you get symptoms such as headache with confusion, seizures (fits) or changes in vision, call your doctor right away. This could be a very rare nervous system side effect named posterior reversible encephalopathy syndrome.</p><p>If you develop breathing difficulties or feel very weak and are very pale please tell your doctor as this may be a sign of kidney failure or problems with your lungs.</p><p>If you develop generalised swelling, shortness of breath or weight gain, please tell your doctor as this may be a sign of fluid leaking from your small blood vessels into the tissue.</p><p><strong>Children and adolescents</strong><br />This medicine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p><p><strong>Other medicines and Gemcitabine Jazeera</strong><br />Please tell your doctor if you are taking, have recently taken or might take any other medicines, including vaccinations and medicines obtained without a prescription.</p><p><strong>Pregnancy, breast-feeding and fertility</strong><br /><em>Pregnancy</em><br />If you are pregnant, or thinking about becoming pregnant, tell your doctor. The use of Gemcitabine Jazeera should be avoided if pregnant. Your doctor will discuss with you the potential risk of taking Gemcitabine Jazeera during pregnancy.</p><p><em>Breast-feeding</em><br />If you are breast-feeding, tell your doctor. You must discontinue breast-feeding during treatment with Gemcitabine Jazeera.<strong><em>&nbsp;</em></strong></p><p><em>Fertility</em><br />Men are advised not to father a child during, and up to 6 months after treatment with gemcitabine. If you would like to father a child during the treatment or in the 6 months following treatment, please seek advice from your doctor or pharmacist. You may want to seek counselling on sperm storage before starting your therapy.</p><p><strong>Driving and using machines</strong><br />Gemcitabine treatment can make you feel drowsy. Alcohol can make this worse. Do not drive or operate machinery until you are sure that gemcitabine has not made you feel sleepy.</p><p><strong>Gemcitabine Jazeera contains sodium</strong><br />Gemcitabine Jazeera contains sodium. Each vial of Gemcitabine Jazeera 200 mg and 1000 mg Powder for Solution for Infusion contains 0.152 mmol (3.5 mg) or 0.762 mmol (17.53 mg) sodium; respectively. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The usual dose of Gemcitabine Jazeera is 1000-1250 mg for every square metre of your body&rsquo;s surface area. Your height and weight are measured to work out the surface area of your body. Your doctor will use this body surface area to work out the right dose for you. This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition.</p><p>How frequently you receive your infusion will depend on the type of cancer you are being treated for.</p><p>A hospital pharmacist or doctor will have dissolved the Gemcitabine Jazeera powder before it is given to you.</p><p>You will always receive Gemcitabine Jazeera by infusion into one of your veins. The infusion will last approximately 30 minutes.</p><p>If you have further questions on the use of this product ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>You must contact your doctor immediately if you notice any of the following: </strong></p><ul><li>Bleeding from the gums, nose or mouth or any bleeding that would not stop, reddish or pinkish urine, unexpected bruising (since you might have less platelets than normal which is very common)</li><li>Tiredness, feeling faint, becoming easily breathless or if you look pale (since you might have less haemoglobin than normal which is very common)</li><li>Mild to moderate skin rash (very common)/itching (common), or fever (very common); (allergic reactions)</li><li>Temperature of 38ᵒC or greater, sweating or other signs of infection (since you might have less white blood cells than normal accompanied by fever also known as febrile neutropenia) (common)</li><li>Pain, redness, swelling or sores in your mouth (stomatitis) (common)</li><li>Irregular heart rate (arrhythmia) (uncommon)</li><li>Extreme tiredness and weakness, purpura or small areas of bleeding in the skin (bruises), acute renal failure (low urine output/or no urine output), and signs of infection. These may be features of thrombotic microangiopathy (clots forming in small blood vessels) (very rare) and haemolytic uraemic syndrome (uncommon), which may be fatal</li><li>Difficulty breathing (it is common to have mild breathing difficulty soon after the gemcitabine infusion which soon passes, however uncommonly or rarely there can be more severe lung problems)</li><li>Sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke (uncommon)</li><li>Severe chest pain (myocardial infarction) (rare)</li><li>Severe hypersensitivity/allergic reaction with severe skin rash including red itchy skin, swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), wheezing, fast beating heart and you may feel you are going to faint (anaphylactic reaction) (very rare)</li><li>Generalised swelling, shortness of breath or weight gain, as you might have fluid leakage from small blood vessels into the tissues (capillary leak syndrome) (very rare)</li><li>Headache with changes in vision, confusion, seizures or fits (posterior reversible encephalopathy syndrome) (very rare)</li><li>Severe rash with itching, blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis) (very rare)</li></ul><p><strong><em>Other side effects with gemcitabine may include:</em></strong><br /><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><ul><li>Low white blood cells</li><li>Difficulty breathing</li><li>Vomiting</li><li>Feeling sick (nausea)</li><li>Hair loss</li><li>Liver problems: found through abnormal blood test results</li><li>Blood in urine</li><li>Abnormal urine tests: protein in urine</li><li>Flu like symptoms including fever</li><li>Swelling of ankles, fingers, feet, face (oedema)</li></ul><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><ul><li>Poor appetite (anorexia)</li><li>Headache</li><li>Difficulty sleeping (insomnia)</li><li>Sleepiness</li><li>Cough</li><li>Runny nose</li><li>Constipation</li><li>Diarrhoea</li><li>Itching</li><li>Sweating</li><li>Muscle pain</li><li>Back pain</li><li>Fever</li><li>Weakness</li><li>Chills</li><li>Infections &nbsp;</li></ul><p><strong>Uncommon side effects </strong>(may affect up to 1 in 100 people)</p><ul><li>Scarring of the air sacs of the lung (interstitial pneumonitis)</li><li>Wheeze (spasm of the airways)</li><li>Scarring of the lungs (abnormal chest X ray/scan)</li><li>Heart failure</li><li>Kidney failure</li><li>Serious liver damage, including liver failure</li></ul><p><strong>Rare side effects </strong>(may affect up to 1 in 1,000 people)</p><ul><li>Low blood pressure</li><li>Skin scaling, ulceration or blister formation</li><li>Sloughing of the skin and severe skin blistering</li><li>Injection site reactions</li><li>Severe lung inflammation causing respiratory failure (adult respiratory distress syndrome)</li><li>A skin rash like severe sunburn which can occur on skin that has previously been exposed to radiotherapy (radiation recall)</li><li>Fluid in the lungs</li><li>Scarring of the air sacs of the lung associated with radiation therapy (radiation toxicity), Gangrene of fingers or toes</li><li>Inflammation of the blood vessels (peripheral vasculitis)</li></ul><p><strong>Very rare side effects </strong>(may affect up to 1 in 10,000 people)</p><ul><li>Increased platelet count</li><li>Inflammation of the lining of the large bowel, caused by reduced blood supply (ischaemic colitis)</li><li>Low haemoglobin level (anaemia), low white blood cells and low platelet count will be detected by a blood test</li><li>Clots forming in small blood vessels (thrombotic microangiopathy)</li></ul><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><ul><li>Skin redness with swelling (Pseudocellulitis)</li><li>When bacteria and their toxins circulate in the blood and starts to damage the organs (sepsis)</li></ul><p>You might have any of these symptoms and/or conditions. You must tell your doctor as soon as possible when you start experiencing any of these side effects.<br />If you are concerned about any side effects, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p><strong>After reconstitution and dilution: </strong></p><p>Gemcitabine Jazeera solutions are stable for 24 hours at controlled room temperature (20 to 25&deg;C).</p><p>From a microbiological point of view, it is advised that the product is used immediately.</p><p>Discard unused portion.</p><p>Solutions of reconstituted Gemcitabine Jazeera should not be refrigerated, as crystallization may occur.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if it contains particles or if it is strongly coloured.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is gemcitabine hydrochloride.</p><p>Each vial of Gemcitabine Jazeera 200 mg Powder for Solution for Infusion contains 228 mg gemcitabine hydrochloride equivalent to 200 mg gemcitabine.</p><p>Each vial of Gemcitabine Jazeera 1000 mg Powder for Solution for Infusion contains 1140 mg gemcitabine hydrochloride equivalent to 1000 mg gemcitabine.</p><p>The other ingredients are mannitol, sodium acetate, hydrochloric acid and sodium hydroxide.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Gemcitabine Jazeera 200 mg and 1000 mg Powder for Solution for Infusion is white to almost white lyophilized powder in clear type I glass vials stoppered with bromobutyl grey stoppers and sealed with aluminium flip-off caps. 

After reconstitution, it is a clear, colourless to light straw-coloured solution.
Pack size: 1 Vial. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Manufacturer</strong><br />Thymoorgan Pharmazie GmbH<br />Schiffgraben 23<br />38690 Goslar<br />Germany<br />Tel: + (49-5324) 77010<br />Fax: + (49- 5324) 770130</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي جيمسيتابين جزيرة إلى مجموعة من الأدوية تسمى &quot;السامة للخلايا&quot;. تقتل هذه الأدوية الخلايا المنقسمة، بما في ذلك الخلايا السرطانية.</p><p dir="RTL">يمكن إعطاء جيمسيتابين جزيرة وحده أو في توليفة مع أدوية أخرى مضادة للسرطان حسب نوع السرطان الذي تعاني منه.</p><p dir="RTL">يُستخدم جيمسيتابين جزيرة في علاج عدد من أنواع السرطان منها:</p><ul dir="rtl"><li>سرطان الرئة ذو الخلايا غير الصغيرة، لوحده أو في توليفة مع سيسبلاتين</li><li>سرطان البنكرياس</li><li>سرطان الثدي، في توليفة مع باكليتاكسيل</li><li>سرطان المبيض، في توليفة مع كاربوبلاتين</li><li>سرطان المثانة، في توليفة مع سيسبلاتين</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب إعطاؤك جيمسيتابين جزيرة</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لجيمسيتابين أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنتِ ترضعين طبيعياً.</li></ul><p dir="RTL">أخبر الطبيب إذا كنت تعتقد أن أياً مما سبق ينطبق عليك.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong><br />سيتم أخذ عينات من دمك قبل التسريب الأول لتقييم إذا ما كانت وظائف الكُلى والكبد طبيعية. سيتم أيضاً أخذ عينات من دمك قبل كل تسريب للتحقق مما إذا كان لديك ما يكفي من خلايا الدم لتلقي جيمسيتابين جزيرة. قد يقرر طبيبك تغيير جرعتك أو تأخير علاجك، اعتماداً على حالتك بشكل عام وإذا كان عدد خلايا الدم لديك منخفضاً جداً.</p><p dir="RTL">سيتم أخذ عينات من دمك بشكل دوري لفحص وظائف الكُلى والكبد.</p><p dir="RTL"><em>تحدث إلى طبيبك، الصيدلي أو الممرض قبل استخدام جيمسيتابين جزيرة:</em></p><p dir="RTL">إذا كنت تعاني حالياً أو عانيت في السابق من مرض في الكبد، مرض في القلب، مرض دموي وعائي أو مشاكل في الكُلى، تحدث مع طبيبك أو صيدلي المستشفى حيث قد لا تتمكن من تلقي جيمسيتابين جزيرة.</p><p dir="RTL">إذا كنت قد خضعت للعلاج بالإشعاع مؤخراً أو قد تخضع له، يُرجى إخبار طبيبك لأنه قد يكون هناك تفاعل إشعاعي مبكر أو متأخر مع جيمسيتابين جزيرة.</p><p dir="RTL">إذا كنت قد حصلت على لقاح مؤخراً، يُرجى إخبار طبيبك حيث قد يتسبب ذلك في حدوث آثار سيئة مع جيمسيتابين جزيرة.</p><p dir="RTL">إذا ظهرت عليك أعراض أثناء العلاج بهذا الدواء مثل صداع مع ارتباك، نوبات (تشنجات) أو تغيرات في الرؤية، اتصل بطبيبك على الفور. قد يكون هذا أثراً جانبياً نادراً جداً على الجهاز العصبي يسمى متلازمة اعتلال الدماغ العكسي الخلفي.</p><p dir="RTL">يُرجى إخبار طبيبك إذا كنت تعاني من صعوبات في التنفس أو تشعر بضعف شديد وشحوب شديد؛ لأن هذا قد يكون علامة على الإصابة بفشل كلوي أو مشاكل في الرئتين لديك.</p><p dir="RTL">يُرجى إخبار طبيبك إذا كنت تعاني من تورم عام، ضيق في التنفس أو زيادة في الوزن؛ لأن هذا قد يكون علامة على تسرب السوائل من الأوعية الدموية الصغيرة إلى الأنسجة.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><br />لا ينصح باستخدام هذا الدواء للأطفال الذين تقل أعمارهم عن 18 عاماً بسبب عدم وجود بيانات كافية متعلقة بالسلامة والفاعلية.</p><p dir="RTL"><strong>الأدوية الأخرى وجيمسيتابين جزيرة</strong><br />يرجى إخبار طبيبك إذا كنت تأخذ، أخذت مؤخراً أو قد تأخذ أي أدوية أخرى، بما في ذلك اللقاحات والأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>الحمل، الرضاعة والخصوبة</strong><br /><em>الحمل</em><br />أخبري طبيبك إذا كنتِ حاملاً، أو تخططين للحمل. يجب تجنب استخدام جيمسيتابين جزيرة إذا كنتِ حاملاً. سيناقش طبيبكِ معك المخاطر المحتملة لأخذ جيمسيتابين جزيرة خلال الحمل.</p><p dir="RTL"><em>الرضاعة</em><br />أخبري طبيبك إذا كنتِ ترضعين رضاعة طبيعية. يجب عليكِ التوقف عن الإرضاع الطبيعي في أثناء العلاج بجيمسيتابين جزيرة.</p><p dir="RTL"><em>الخصوبة</em><br />يُنصح الرجال بعدم الإنجاب في أثناء العلاج وحتى مرور ستة أشهر بعد العلاج باستخدام جيمسيتابين. يُرجى طلب المشورة من طبيبك أو الصيدلي إذا كنت ترغب في إنجاب طفل أثناء العلاج أو في الأشهر الستة التي تعقب العلاج. قد ترغب في طلب المشورة حول تخزين الحيوانات المنوية قبل بدء علاجك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />يمكن أن يُشعرك العلاج بجيمسيتابين بالنعاس. يمكن للكحول أن يزيد الأمر سوءاً. لا تقم بقيادة السيارة أو تشغل الآلات حتى تتأكد من أن جيمسيتابين لم يشعرك بالنعاس.</p><p dir="RTL"><strong>يحتوي جيمسيتابين جزيرة على الصوديوم</strong><br />يحتوي جيمسيتابين جزيرة على الصوديوم. تحتوي كل زجاجة من جيمسيتابين جزيرة 200 ملغم و1000 ملغم مسحوق للحل للتسريب على 0.152 ملمول (3.5 ملغم) أو 0.762 ملمول (17.53 ملغم) صوديوم؛ على التوالي. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، فيمكن اعتباره أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الجرعة المعتادة من جيمسيتابين جزيرة تتراوح بين 1000-1250 ملغم لكل متر مربع من مساحة سطح الجسم. يتم قياس طولك ووزنك لمعرفة مساحة سطح جسمك. سيستعين طبيبك بمساحة سطح الجسم هذه لتحديد الجرعة المناسبة لك. يمكن تعديل هذه الجرعة، أو قد يتأخر العلاج وذلك حسب عدد خلايا الدم لديك وعلى حالتك العامة.</p><p dir="RTL">سوف يعتمد عدد المرات التي تتلقى فيها التسريب على نوع السرطان الذي تعالج منه.</p><p dir="RTL">سيقوم صيدلي المستشفى أو الطبيب بتذويب مسحوق جيمسيتابين جزيرة قبل إعطائه لك.</p><p dir="RTL">ستحصل دائماً على جيمسيتابين جزيرة عن طريق التسريب في أحد الأوردة لديك. سيستمر التسريب لمدة 30 دقيقة تقريباً.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا المستحضر، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>يجب أن تتواصل مع طبيبك على الفور إذا لاحظت أياً مما يلي: </strong></p><ul dir="rtl"><li>نزف من اللثة، الأنف أو الفم أو أي نزف لا يتوقف، بول محمر أو وردي اللون، تكدم غير متوقع (حيث قد تكون نسبة الصفائح الدموية لديك أقل من الطبيعي وهو أمر شائع جداً)</li><li>تعب، شعور بالإعياء، ضيق التنفس بسهولة أو إذا بدوت شاحباً (حيث قد تكون نسبة الهيموغلوبين لديك أقل من الطبيعي وهو أمر شائع جداً)</li><li>طفح جلدي خفيف إلى متوسط (شائع جداً)/حكة (شائعة)، أو حمّى (شائعة جداً)؛ (ردود فعل تحسسية)</li><li>درجة حرارة 38&deg; مئوية أو أكثر، تعرق أو علامات عدوى أخرى (حيث قد يكون لديك خلايا دم بيضاء أقل من الطبيعي مصحوبة بحمّى تُعرف أيضاً باسم قلة العدلات الحموية) (شائعة)</li><li>ألم، احمرار، تورم أو قرح في فمك (التهاب الفم) (شائعة)</li><li>معدل ضربات قلب غير منتظم (اضطراب قلبي) (غير شائعة)</li><li>تعب وضعف شديدين، فُرفُرية أو نزف في مناطق صغيرة من الجلد (كدمات)، فشل كُلوي حاد (قلة التبول/أو عدم خروج البول)، وعلامات عدوى. قد تكون هذه علامات على الإصابة باعتلال الأوعية الدقيقة الخثاري (تكون الجلطات في الأوعية الدموية الصغيرة) (نادرة جداً) ومتلازمة انحلال الدم اليوريمية (غير شائعة)، التي قد تؤدي إلى الوفاة</li><li>صعوبة في التنفس (من الشائع أن تعاني من صعوبة خفيفة في التنفس بعد فترة وجيزة من الحقن بجيمسيتابين التي ما تنتهي بسرعة، ولكن من غير الشائع أو نادراً ما يكون هناك مشاكل رئوية أكثر حدة)</li><li>ضعف أو تنميل مفاجئ في الوجه، الذراعين أو الساقين لديك، خاصةً في جانب واحد، أو تلعثم الكلام، حتى لفترة قصيرة من الزمن. قد تكون هذه علامات لسكتة دماغية (غير شائعة)</li><li>ألم شديد في الصدر (الاحتشاء القلبي) (حالة نادرة)</li><li>فرط حساسية/رد فعل تحسسي حاد يصاحبه طفح جلدي حاد يشمل احمراراً وحكة في الجلد، تورم في اليدين، القدمين، الكاحلين، الوجه، الشفتين، الفم أو الحنجرة (ما قد يسبب صعوبة في البلع أو التنفس)، صفير، سرعة ضربات القلب وقد تشعر بالإغماء (رد فعل تأقيّ) (نادرة جداً)</li><li>ورم بشكل عام، ضيق في التنفس أو زيادة الوزن، حيث قد تكون مصاباً بتسرب السوائل من الأوعية الدموية الصغيرة إلى الأنسجة (متلازمة التسرب الشعري) (نادرة جداً)</li><li>صداع يصاحبه تغيرات في الرؤية، ارتباك، نوبات أو تشنجات (متلازمة اعتلال الدماغ الخلفي العكسي) (نادرة جداً)</li><li>طفح حاد مصحوب بحكة، تقرح أو تقشير في الجلد (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي) (نادرة جداً)</li></ul><p dir="RTL"><strong><em>قد تشمل الآثار الجانبية الأخرى مع جيمسيتابين: </em></strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً </strong>(قد تؤثر في أكثر من شخص واحد من كل 10 أشخاص)</p><ul dir="rtl"><li>انخفاض عدد خلايا الدم البيضاء</li><li>صعوبة في التنفس</li><li>تقيؤ</li><li>شعور بالإعياء (غثيان)</li><li>تساقط الشعر</li><li>مشاكل في الكبد: اُكتشفت من خلال نتائج فحص الدم غير الطبيعية</li><li>دم في البول</li><li>اختبارات البول غير الطبيعية: وجود بروتين في البول</li><li>أعراض شبيهة بأعراض الأنفلونزا بما في ذلك حمّى</li><li>تورم الكاحلين، الأصابع، القدمين، الوجه (وذمة)</li></ul><p dir="RTL"><strong>آثار جانبية شائعة </strong>(قد تؤثر فيما يصل إلى شخص واحد من كل 10 أشخاص)</p><ul dir="rtl"><li>ضعف الشهية (فقدان الشهية)</li><li>صداع</li><li>صعوبة في النوم (أرق)</li><li>نعاس</li><li>سعال</li><li>سيلان الأنف</li><li>إمساك</li><li>إسهال</li><li>حكة</li><li>تعرق</li><li>ألم في العضلات</li><li>ألم في الظهر</li><li>حمّى</li><li>ضعف</li><li>قشعريرة</li><li>عدوى&nbsp;</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة </strong>(قد تؤثر فيما يصل إلى شخص واحد من كل 100 شخص)</p><ul dir="rtl"><li>تندب الأكياس الهوائية للرئة (الالتهاب الرئوي الخلالي)</li><li>صفير (تشنج في الشعب الهوائية)</li><li>تندب الرئتين (أشعة/مسح سيني على الصدر غير طبيعي)</li><li>فشل قلبي</li><li>فشل كُلوي</li><li>تلف حاد في الكبد، يشمل ذلك الفشل الكبدي</li></ul><p dir="RTL"><strong>آثار جانبية نادرة</strong> (قد تؤثر فيما يصل إلى شخص واحد من كل 1000 شخص)</p><ul dir="rtl"><li>انخفاض ضغط الدم</li><li>قشور الجلد، التقرح أو تكوّن بثور</li><li>تمزق الجلد وتبثر حاد في الجلد</li><li>تفاعلات في موضع الحقن</li><li>التهاب رئوي حاد يسبب فشل تنفسي (متلازمة الضائقة التنفسية الحادة)</li><li>طفح جلدي مثل حروق الشمس الشديدة التي يمكن أن تحدث على الجلد الذي سبق أن تعرض للعلاج الإشعاعي (الاستدعاء الإشعاعي)</li><li>وجود سوائل في الرئتين</li><li>تندب الأكياس الهوائية في الرئة المصاحب للعلاج الإشعاعي (السمية الإشعاعية)، غرغرينا في أصابع اليدين أو القدمين</li><li>التهاب الأوعية الدموية (التهاب الأوعية الدموية الطرفية)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جداً </strong>(قد تؤثر فيما يصل إلى شخص واحد من كل 10000 شخص)</p><ul dir="rtl"><li>زيادة عدد الصفائح الدموية</li><li>التهاب بطانة الأمعاء الغليظة الناجم عن نقص إمداد الدم (التهاب القولون الإقفاري)</li><li>سيتم الكشف عن انخفاض مستوى الهيموغلوبين (فقر الدم)، انخفاض خلايا الدم البيضاء وانخفاض عدد الصفائح الدموية عن طريق فحص الدم</li><li>تشكل الجلطات في الأوعية الدموية الصغيرة (اعتلال الأوعية الدقيقة الخثاري)</li><li>&nbsp;</li></ul><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل تكراراها من البيانات المتاحة)</p><ul dir="rtl"><li>احمرار الجلد مع تورم (التهاب الأنسجة الخلوية الزائف)</li><li>عندما تنتشر البكتيريا وسمومها في الدم وتبدأ في إتلاف الأعضاء (تسمم الدم)</li></ul><p dir="RTL">قد تعاني من أي من هذه الأعراض و/أو الحالات. يجب أن تخبر طبيبك في أقرب وقت ممكن فور إصابتك بأي من هذه الآثار الجانبية.</p><p dir="RTL">إذا كنت قلقاً بشأن أي من الآثار الجانبية، تحدث مع طبيبك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL"><strong>بعد الحل والتخفيف: </strong></p><p dir="RTL">تكون محاليل جيمسيتابين جزيرة مستقرة لمدة 24 ساعة عند درجة حرارة الغرفة المتحكم بها (20 إلى 25&deg; مئوية).</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يُنصح باستخدام المستحضر على الفور.</p><p dir="RTL">تخلص من الكمية غير المستخدمة. &nbsp;</p><p dir="RTL">يجب عدم وضع المحاليل المحضرة من جيمسيتابين جزيرة في الثلاجة، حيث قد يحدث تبلور.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا كان يحتوي على جسيمات أو إذا كان لونه غامق.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي هيدروكلوريد الجيمسيتابين.</p><p dir="RTL">تحتوي كل زجاجة من جيمسيتابين جزيرة 200 ملغم مسحوق للحل للتسريب على 228 ملغم هيدروكلوريد الجيمسيتابين يكافئ 200 ملغم جيمسيتابين.</p><p dir="RTL">&nbsp;تحتوي كل زجاجة من جيمسيتابين جزيرة 1000 ملغم مسحوق للحل للتسريب على 1140 ملغم هيدروكلوريد الجيمسيتابين يكافئ 1000 ملغم جيمسيتابين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانیتول، أسیتات الصودیوم، حمض الھیدروكلوریك وھیدروكسید الصودیوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">جيمسيتابين جزيرة 200 ملغم و1000 ملغم مسحوق للحل للتسريب هو مسحوق مجفف بالتجميد لونه أبيض مائل لشبه الأبيض في زجاجات شفافة من النوع رقم واحد مغلقة بسدادات رمادية من البروموبوتيل ومحكمة الإغلاق بأغطية قابلة للفتح للأعلى من الألمنيوم.</p><p dir="RTL">بعد الحل، يكون المحلول صافٍ، عديم اللون يميل إلى اللون الأصفر الفاتح.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><br />شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong><br />شركة أدوية ثايمورغان ذات المسؤولية المحدودة<br />شارع شيفجرابين 23<br />38690 غوسلار<br />ألمانيا<br />هاتف: 77010 (5324-49) +<br />فاكس: 770130 (5324-49) +</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong><br />تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2024؛ رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gemcitabine Jazeera 200 mg Powder for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 228 mg gemcitabine hydrochloride equivalent to 200 mg gemcitabine.

Excipient with known effect: Sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Infusion.

White to almost white lyophilized powder. 

After reconstitution, it is a clear, colourless to light straw-coloured solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Bladder Cancer:</strong><br />Locally advanced or metastatic bladder cancer, in combination with cisplatin.</p><p><strong>Pancreatic Cancer:</strong><br />Locally advanced or metastatic adenocarcinoma of the pancreas.</p><p><strong>Non-Small Cell Lung Cancer:</strong><br />First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer, in combination with cisplatin. Gemcitabine Jazeera monotherapy can be considered in elderly patients or those with performance status 2.</p><p><strong>Ovarian Cancer:</strong><br />Locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first line therapy.</p><p><strong>Breast Cancer:</strong><br />Unresectable, locally recurrent or metastatic breast cancer, in combination with paclitaxel, in patients experiencing a relapse after adjuvant/neoadjuvant chemotherapy. The preceding chemotherapy should have included an anthracycline, unless clinically contraindicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For intravenous infusion, following reconstitution. Upon reconstitution a colourless or slightly yellow solution is produced.</p><p><strong>Gemcitabine Jazeera</strong> <strong>should only be prescribed by a physician qualified in the use of anti-cancer chemotherapy.</strong><br /><strong>Bladder cancer (combination therapy):</strong><br /><em>Adults:</em>&nbsp;The recommended dose for gemcitabine is 1000 mg/m<sup>2</sup>, given as a 30 minute infusion. The dose should be given on days 1, 8, and 15 of each 28 day cycle in combination with cisplatin. Cisplatin is given at a recommended dose of 70 mg/m<sup>2</sup>&nbsp;on day 1 following gemcitabine, or day 2 of each 28 day cycle. This four week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Pancreatic Cancer:</strong><br /><em>Adults:&nbsp;</em>The recommended dose of gemcitabine is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion. This should be repeated once weekly for up to 7 weeks, followed by a one week rest period. Subsequent cycles should consist of gemcitabine infusions once weekly for 3 consecutive weeks out of every four weeks. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Non-small cell lung cancer (monotherapy):</strong><br /><em>Adults:</em>&nbsp;The recommended dose of gemcitabine is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion. This should be repeated once weekly for three weeks, followed by a one week rest period. This four-week cycle is then repeated. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Non-small cell lung cancer (combination therapy):</strong><br /><em>Adults:</em>&nbsp;The recommended dose of gemcitabine is 1250 mg/m<sup>2</sup>, given by 30 minute intravenous infusion, on days 1 and 8 of each 21 day cycle. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p>Cisplatin has been used at doses between 75-100 mg/m<sup>2</sup>&nbsp;once every 3 weeks.</p><p><strong>Ovarian cancer (combination therapy):</strong><br />The recommended dose of gemcitabine, when used in combination with carboplatin, is 1000 mg/m<sup>2</sup>, given by 30 minute intravenous infusion on days 1 and 8 of each 21 day cycle. After gemcitabine, carboplatin will be given on day 1, consistent with a target Area Under Curve (AUC) of 4.0mg/ml/min. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient.</p><p><strong>Breast cancer (combination therapy):</strong><br /><em>Adults:&nbsp;</em>It is recommended that gemcitabine is used together with paclitaxel according to the following procedure:</p><p>Paclitaxel (175 mg/m<sup>2</sup>) is intravenously infused over 3 hours on day 1, followed by gemcitabine (1250 mg/m<sup>2</sup>) intravenously infused for 30 minutes on days 1 and 8 of each 21 day treatment cycle. Dosage reduction with each cycle or within a cycle may be applied based upon the amount of toxicity experienced by the patient. The absolute granulocyte count should be at least 1.5 x 10<sup>9</sup>/l before treatment with the gemcitabine + paclitaxel combination.</p><p><strong><em>Monitoring for toxicity and dose modification due to toxicity</em><br />Dosage adjustment due to non haematological toxicity:</strong><br />Periodic physical examination and checks of renal and hepatic function should be made to detect non-haematological toxicity. Dosage reduction with each cycle or within a cycle may be applied, based upon the amount of toxicity experienced by the patient. In general, for severe (Grade 3 or 4) non-haematological toxicity, except nausea/vomiting, therapy with gemcitabine should be withheld or decreased depending on the judgement of the treating physician. Doses should be withheld until toxicity has been resolved.</p><p>For cisplatin, carboplatin, and paclitaxel dosage adjustment in combination therapy, please refer to the corresponding Summary of Product Characteristics.</p><p><strong>Dosage adjustment in the presence of haematological toxicity:</strong><br /><em>Initiation of a cycle</em><br />For all indications, patients must be monitored before each dose for platelet and granulocyte counts. Patients should have an absolute granulocyte count of at least 1,500 (x10<sup>6</sup>/l) and a platelet count of 100,000 (x10<sup>6</sup>/l) prior to the administration of a cycle.</p><p><em>Within a cycle</em><br />Dose modifications of gemcitabine within a cycle should be performed according to the following tables:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for bladder cancer, pancreatic cancer, and NSCLC, given in monotherapy or in combination with cisplatin</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>0.5-1</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>50-100</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.5</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;50</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle before the absolute granulocyte count reaches at least 0.5(x 10<sup>9</sup>/l) and the platelet count reaches 50 (x 10<sup>9</sup>/l).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for ovarian cancer, given in combination with carboplatin</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt;1.5</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;100</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1-1.5</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>75-100</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;1</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;75</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle. Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1.5(x 10<sup>9</sup>/l) and the platelet count reaches 100 (x 10<sup>9</sup>/l)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Dose modification of gemcitabine within a cycle for breast cancer, given in combination with paclitaxel</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Absolute Granulocyte Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>Platelet Count</strong></p><p><strong>(x 10<sup>9</sup>/l)</strong></p></td><td style="vertical-align:top"><p><strong>% of Total Dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge;1.2</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&gt;75</p></td><td style="vertical-align:top"><p>100</p></td></tr><tr><td style="vertical-align:top"><p>1-&lt;1.2</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>50-75</p></td><td style="vertical-align:top"><p>75</p></td></tr><tr><td style="vertical-align:top"><p>0.7-&lt;1</p></td><td style="vertical-align:top"><p>and</p></td><td style="vertical-align:top"><p>&ge;50</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>&lt;0.7</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>&lt;50</p></td><td style="vertical-align:top"><p>Withhold*</p></td></tr></tbody></table><p>*Withheld treatment will not be reinstated within a cycle. Treatment will start on day 1 of the next cycle once the absolute granulocyte count reaches at least 1.5 (x 10<sup>9</sup>/l) and the platelet count reaches 100 (x 10<sup>9</sup>/l).</p><p><strong>Dose adjustment due to haematological toxicity in subsequent cycles, for all indications</strong><br />The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of the following haematological toxicities:</p><ul><li>Absolute granulocyte count &lt; 0.5 x 10<sup>9</sup>/l for more than 5 days</li><li>Absolute granulocyte count &lt; 0.1 x 10<sup>9</sup>/l for more than 3 days</li><li>Febrile neutropaenia</li><li>Platelets &lt;25 x 10<sup>9</sup>/l</li><li>Cycle delay of more than one week due to toxicity</li></ul><p><strong>Method of administration</strong><br />Gemcitabine is tolerated well during infusion and may be administered ambulant. If extravasation occurs, generally the infusion must be stopped immediately and started again in another blood vessel. The patient should be monitored carefully after the administration.</p><p>For instructions on reconstitution, see section 6.6</p><p><strong><em>Special Populations</em><br />Patients with hepatic or renal impairment:</strong><br />Gemcitabine should be used with caution in patients with hepatic or renal impairment as there is insufficient information from clinical studies to allow for clear dose recommendations for these patient populations (see sections 4.4 and 5.2).</p><p><strong>Elderly population (&gt;65 years):</strong><br />Gemcitabine has been well tolerated in patients over the age of 65. There is no evidence to suggest that dose adjustments, other than those already recommended for all patients, are necessary in the elderly (see section 5.2).</p><p><strong>Paediatric population (&lt;18 years):</strong><br />Gemcitabine is not recommended for use in children under 18 years of age due to insufficient data on safety and efficacy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to gemcitabine or to any of the excipients.

Breast-feeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity.</p><p><strong>Haematological toxicity</strong><br />Gemcitabine can suppress bone marrow function as manifested by leucopaenia, thrombocytopaenia, and anaemia.</p><p>Patients receiving gemcitabine should be monitored prior to each dose for platelet, leucocyte and granulocyte counts. Suspension or modification of therapy should be considered when drug-induced bone marrow depression is detected (see section 4.2). However, myelosuppression is short lived and usually does not result in dose reduction and rarely in discontinuation.</p><p>Peripheral blood counts may continue to deteriorate after gemcitabine administration has been stopped. In patients with impaired bone marrow function, the treatment should be started with caution. As with other cytotoxic treatments, the risk of cumulative bone-marrow suppression must be considered when gemcitabine treatment is given together with other chemotherapy.</p><p><strong>Hepatic impairment</strong><br />Administration of gemcitabine to patients with concurrent liver metastases or a pre-existing medical history of hepatitis, alcoholism or cirrhosis of the liver may result in exacerbation of the underlying liver impairment.</p><p>Laboratory evaluation of renal and hepatic function (including virological tests) should be performed periodically.</p><p>Gemcitabine should be used with caution in patients with hepatic insufficiency or with impaired renal function as there is insufficient information from clinical studies to allow clear dose recommendation for this patient population (see section 4.2).</p><p><strong>Concomitant radiotherapy</strong><br />Concomitant radiotherapy (given together or &le;7 days apart): Toxicity has been reported (see section 4.5 for details and recommendations for use).</p><p><strong>Live vaccinations</strong><br />Yellow fever vaccine and other live attenuated vaccines are not recommended in patients treated with gemcitabine (see section 4.5).</p><p><strong>Posterior reversible encephalopathy syndrome</strong><br />Reports of posterior reversible encephalopathy syndrome (PRES) with potentially severe consequences have been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents. Acute hypertension and seizure activity were reported in most gemcitabine patients experiencing PRES, but other symptoms such as headache, lethargy, confusion and blindness could also be present. Diagnosis is optimally confirmed by magnetic resonance imaging (MRI). PRES was typically reversible with appropriate supportive measures. Gemcitabine should be permanently discontinued and supportive measures implemented, including blood pressure control and anti-seizure therapy, if PRES develops during therapy.</p><p><strong>Cardiovascular</strong><br />Due to the risk of cardiac and/or vascular disorders with gemcitabine, particular caution must be exercised with patients presenting a history of cardiovascular events.</p><p><em>Capillary leak syndrome</em><br />Capillary leak syndrome has been reported in patients receiving gemcitabine as single agent or in combination with other chemotherapeutic agents (see section 4.8). The condition is usually treatable if recognised early and managed appropriately, but fatal cases have been reported. The condition involves systemic capillary hyperpermeability during which fluid and proteins from the intravascular space leak into the interstitium. The clinical features include generalised oedema, weight gain, hypoalbuminaemia, severe hypotension, acute renal impairment and pulmonary oedema. Gemcitabine should be discontinued and supportive measures implemented if capillary leak syndrome develops during therapy. Capillary leak syndrome can occur in later cycles and has been associated in the literature with adult respiratory distress syndrome.</p><p><strong>Pulmonary</strong><br />Pulmonary effects, sometimes severe (such as pulmonary oedema, interstitial pneumonitis, or adult respiratory distress syndrome (ARDS), have been reported in association with gemcitabine therapy. The aetiology of these effects is unknown. If such effects develop, consideration should be given to discontinuing gemcitabine therapy. Early use of supportive care measures may help ameliorate the condition.</p><p><strong>Renal</strong><br />Clinical findings consistent with the haemolytic uraemic syndrome (HUS) were rarely reported in patients receiving gemcitabine (see section 4.8). HUS is a life-threatening disease. Treatment should be discontinued at the first signs of any evidence of micro-angiopathic haemolytic anaemia, such as rapidly falling haemoglobin levels with concurrent thrombocytopenia, elevation of serum bilirubin, serum creatinine, blood urea nitrogen or lactate dehydrogenase (LDH). Renal failure may not be reversible with discontinuation of therapy, and dialysis may be required.</p><p><strong>Fertility</strong><br />In fertility studies, gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine (see section 4.6).</p><p><strong>Gemcitabine Jazeera contains sodium</strong><br />Gemcitabine Jazeera contains sodium. Each vial of Gemcitabine Jazeera 200 Powder for Solution for Infusion contains 0.152 mmol (3.5 mg) sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>This medicinal product may be reconstituted with sodium-containing solutions (see section 6.6) and this should be considered in relation to the total sodium from all sources that will be administered to the patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific interaction studies have been performed (see section 5.2)</p><p><strong>Radiotherapy</strong><br /><em>Concurrent (given together or &le; 7 days apart)</em>&nbsp;- Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume.</p><p>Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity. In a single trial, where gemcitabine at a dose of 1,000 mg/m<sup>2&nbsp;</sup>was administered concurrently for up to 6 consecutive weeks with therapeutic thoracic radiation to patients with non-small cell lung cancer, significant toxicity in the form of severe, and potentially life threatening mucositis, especially oesophagitis, and pneumonitis was observed, particularly in patients receiving large volumes of radiotherapy [median treatment volumes 4,795 cm<sup>3</sup>]. Studies done subsequently have suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of 66 Gy were applied concomitantly with an administration with gemcitabine (600 mg/m<sup>2</sup>, four times) and cisplatin (80 mg/m<sup>2</sup>&nbsp;twice) during 6 weeks. The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.</p><p><em>Non-concurrent (given &gt;7 days apart) -</em>&nbsp;Available information does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall. Data suggest that gemcitabine can be started after the acute effects of radiation have resolved or at least one week after radiation.</p><p>Radiation injury has been reported on targeted tissues (e.g. oesophagitis, colitis, and pneumonitis) in association with both concurrent and non-concurrent use of gemcitabine.</p><p><strong>Others</strong><br />Yellow fever and other live attenuated vaccines are not recommended due to the risk of systemic, possibly fatal, disease, particularly in immunosuppressed patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy:</strong><br />There are no adequate data from the use of gemcitabine in pregnant patients. Studies in animals have shown reproductive toxicity (see section 5.3). Based on results from animal studies and the mechanism of action of gemcitabine, this substance should not be used during pregnancy, unless clearly necessary. Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur.</p><p><strong>Breast feeding:</strong><br />It is not known whether gemcitabine is excreted in human milk and adverse events on the suckling child cannot be excluded. Breast-feeding must be discontinued during gemcitabine therapy.</p><p><strong>Fertility:</strong><br />In fertility studies, gemcitabine caused hypospermatogenesis in male mice (see section 5.3). Therefore, men being treated with gemcitabine are advised not to father a child during and up to 6 months after treatment and to seek further advice regarding cryoconservation of sperm prior to treatment because of the possibility of infertility due to therapy with gemcitabine.<strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, gemcitabine has been reported to cause mild to moderate somnolence, especially in combination with alcohol consumption. Patients should be cautioned against driving or operating machinery until it is established that they do not become somnolent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions associated with gemcitabine treatment include: nausea, with or without vomiting, and raised liver transaminases ( (AST/ ALT) and alkaline phosphatase, reported in approximately 60% of patients; proteinuria and haematuria reported in approximately 50% of patients; dyspnoea reported in 10-40% of patients (highest incidence in lung cancer patients); allergic skin rashes occurring in approximately 25% of patients, and are associated with itching in 10% of patients.</p><p>The frequency and severity of the adverse reactions are affected by the dose, infusion rate, and intervals between doses (see section 4.4). Dose-limiting adverse reactions are reductions in thrombocyte, leucocyte, and granulocyte counts (see section 4.2).</p><p><strong>Clinical trial data</strong><br />Frequencies are defined as: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Grouping</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Infections</p><p>&nbsp;</p><p><em>Not known:</em></p><p>&middot;&nbsp;&nbsp; Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Leucopenia (Neutropaenia grade 3 =19.3% ; grade 4 =6%)</p><p>&middot;&nbsp;&nbsp; Thrombocytopaenia</p><p>&middot;&nbsp;&nbsp; Anaemia</p><p>Bone marrow suppression is usually mild to moderate and mostly affects the granulocyte count (see section 4.2)</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Febrile neutropenia</p><p><em>Very rare:</em></p><p>&middot;&nbsp;&nbsp; Thrombocytosis</p><p>&middot;&nbsp;&nbsp; Thrombotic microangiopathy</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p><em>Very rare:</em></p><p>&middot;&nbsp;&nbsp; Anaphylactoid reaction</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp; Insomnia</p><p>&middot;&nbsp;&nbsp; Somnolence</p><p><em>Uncommon:</em></p><p>&middot;&nbsp;&nbsp; Cerebrovascular accident</p><p><em>Very rare:</em></p><p>&middot;&nbsp;&nbsp; Posterior reversible encephalopathy syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p><em>Uncommon:</em></p><p>&middot;&nbsp;&nbsp; Arrhythmias, predominantly supraventricular in nature</p><p>&middot;&nbsp;&nbsp; Heart failure</p><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Myocardial infarct</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Clinical signs of peripheral vasculitis and gangrene</p><p>&middot;&nbsp;&nbsp; Hypotension</p><p><em>Very Rare:</em></p><p>&middot;&nbsp;&nbsp; Capillary leak syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Dyspnoea -usually mild and passes rapidly without treatment</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp; Rhinitis</p><p><em>Uncommon:</em></p><p>&middot;&nbsp;&nbsp; Interstitial pneumonitis (see section 4.4)</p><p>&middot;&nbsp;&nbsp; Bronchospasm &ndash; usually mild and transient but may require parenteral treatment</p><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Pulmonary oedema</p><p>&middot;&nbsp;&nbsp; Adult respiratory distress syndrome (see section 4.4)</p><p><em>Not known:</em></p><p>&middot;&nbsp;&nbsp; Pulmonary eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Vomiting</p><p>&middot;&nbsp;&nbsp; Nausea</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp; Stomatitis &amp; ulceration of the mouth</p><p>&middot;&nbsp;&nbsp; Constipation</p><p><em>Very rare:</em></p><p>&middot;&nbsp;&nbsp; Ischaemic colitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Elevation of liver transaminases (AST and ALT) and alkaline phosphatase</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Increased bilirubin</p><p><em>Uncommon:</em></p><p>&middot;&nbsp;&nbsp; Serious hepatotoxicity, including liver failure and death</p><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Increased gamma glutamyl transferase (GGT)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Allergic skin rash frequently associated with pruritus</p><p>&middot;&nbsp;&nbsp; Alopecia</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp; Sweating</p><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Severe skin reactions, including desquamation and bullous skin eruptions</p><p>&middot;&nbsp;&nbsp; Ulceration</p><p>&middot;&nbsp;&nbsp; Vesicle and sore formation</p><p>&middot;&nbsp;&nbsp; Scaling</p><p><em>Very rare:</em></p><p>&middot;&nbsp;&nbsp; Toxic epidermal necrolysis</p><p>&middot;&nbsp;&nbsp; Stevens-Johnson Syndrome</p><p><em>Not known</em></p><p>&middot;&nbsp;&nbsp; Pseudocellulitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Back pain</p><p>&middot;&nbsp;&nbsp; Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Haematuria</p><p>&middot;&nbsp;&nbsp; Mild proteinurea</p><p><em>Uncommon:</em></p><p>&middot;&nbsp;&nbsp; Renal failure (see section 4.4)</p><p>&middot;&nbsp;&nbsp; Haemolytic uraemic syndrome (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em>Very common:</em></p><p>&middot;&nbsp;&nbsp; Influenza-like symptoms -the most common symptoms are fever, headache, chills, myalgia, asthenia, and anorexia. Cough, rhinitis, malaise, perspiration and sleeping difficulties have also been reported.</p><p>&middot;&nbsp;&nbsp; Oedema/peripheral oedema &ndash; including facial oedema. Oedema is usually reversible after stopping treatment</p><p><em>Common:</em></p><p>&middot;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp; Asthenia</p><p>&middot;&nbsp;&nbsp; Chills</p><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Injection site reactions -mainly mild in nature</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning, and procedural complications</p></td><td style="vertical-align:top"><p><em>Rare:</em></p><p>&middot;&nbsp;&nbsp; Radiation toxicity (see section 4.5)</p><p>&middot;&nbsp;&nbsp; Radiation recall</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Combination use in breast cancer</strong></p><p>The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when gemcitabine is used in combination with paclitaxel. However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events. Fatigue and febrile neutropaenia occur more frequently when gemcitabine is used in combination with paclitaxel. Fatigue, which is not associated with anaemia, usually resolves after the first cycle.</p><p><strong>Grade 3 and 4 Adverse Events. Paclitaxel versus gemcitabine plus paclitaxel:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong><u>Paclitaxel Arm&nbsp;</u></strong><strong><u>(n= 259)</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus Paclitaxel Arm (n= 262)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>5(1.9)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>3 (1.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neutropaenia</strong></p></td><td style="vertical-align:top"><p>11 (4.2)</p></td><td style="vertical-align:top"><p>17 (6.6)*</p></td><td style="vertical-align:top"><p>82 (31.3)</p></td><td style="vertical-align:top"><p>45 (17.2)*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Febrile neutropenia</strong></p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>12 (4.6)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Fatigue</strong></p></td><td style="vertical-align:top"><p>3 (1.2)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td><td style="vertical-align:top"><p>15 (5.7)</p></td><td style="vertical-align:top"><p>2 (0.8)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>5 (1.9)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>8(3.1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><strong>Motor neuropathy</strong></p></td><td style="vertical-align:top"><p>2 (0.8)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>6 (2.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sensory neuropathy</strong></p></td><td style="vertical-align:top"><p>9 (3.5)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>14 (5.3)</p></td><td style="vertical-align:top"><p>1 (0.4)</p></td></tr></tbody></table><p>* Grade 4 neutropenia lasting for more than 7 days occurred in 12.6% of patients in the combination arm and 5.0% of patients in the paclitaxel arm.</p><p><strong>Combination use in bladder cancer</strong></p><p><strong>Grade 3 and 4 Adverse Events. </strong><strong>MVAC versus gemcitabine plus cisplatin:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) Arm (n= 196)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus cisplatin Arm (n= 200)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>30 (16)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td style="vertical-align:top"><p>47 (24)</p></td><td style="vertical-align:top"><p>7 (4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>15 (8)</p></td><td style="vertical-align:top"><p>25 (13)</p></td><td style="vertical-align:top"><p>57 (29)</p></td><td style="vertical-align:top"><p>57 (29)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nausea and vomiting</strong></p></td><td style="vertical-align:top"><p>37 (19)</p></td><td style="vertical-align:top"><p>3 (2)</p></td><td style="vertical-align:top"><p>44 (22)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Diarrhoea</strong></p></td><td style="vertical-align:top"><p>15 (8)</p></td><td style="vertical-align:top"><p>1 (1)</p></td><td style="vertical-align:top"><p>6 (3)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p>19 (10)</p></td><td style="vertical-align:top"><p>10 (5)</p></td><td style="vertical-align:top"><p>4 (2)</p></td><td style="vertical-align:top"><p>1 (1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stomatitis</strong></p></td><td style="vertical-align:top"><p>34 (18)</p></td><td style="vertical-align:top"><p>8 (4)</p></td><td style="vertical-align:top"><p>2 (1)</p></td><td style="vertical-align:top"><p>0 (0)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Combination use in ovarian cancer</strong></p><p><strong>Grade 3 and 4 Adverse Events. Carboplatin versus gemcitabine plus carboplatin:</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="3" style="vertical-align:top">&nbsp;</td><td colspan="4" style="vertical-align:top"><p><strong>Number (%) of Patients</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Carboplatin Arm</strong></p><p><strong>(n= 174)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Gemcitabine plus carboplatin Arm (n= 175)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td><td style="vertical-align:top"><p><strong>Grade 3</strong></p></td><td style="vertical-align:top"><p><strong>Grade 4</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Anaemia</strong></p></td><td style="vertical-align:top"><p>10 (5.7)</p></td><td style="vertical-align:top"><p>4 (2.3)</p></td><td style="vertical-align:top"><p>39 (22.3)</p></td><td style="vertical-align:top"><p>9 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Neutropaenia</strong></p></td><td style="vertical-align:top"><p>19 (10.9)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>73 (41.7)</p></td><td style="vertical-align:top"><p>50 (28.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Thrombocytopaenia</strong></p></td><td style="vertical-align:top"><p>18 (10.3)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>53 (30.3)</p></td><td style="vertical-align:top"><p>8 (4.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Leucopaenia</strong></p></td><td style="vertical-align:top"><p>11 (6.3)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td><td style="vertical-align:top"><p>84 (48.0)</p></td><td style="vertical-align:top"><p>9 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Non-laboratory</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>3 (1.8)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Febrile neutropaenia</strong></p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>2 (1.1)</p></td><td style="vertical-align:top"><p>(0.0)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infection without neutropaenia</strong></p></td><td style="vertical-align:top"><p>0 (0)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>(0.0)</p></td><td style="vertical-align:top"><p>1 (0.6)</p></td></tr></tbody></table><p>Sensory neuropathy was also more frequent in the combination arm than with single agent carboplatin.</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no known antidote for overdose of gemcitabine. Single doses of up to 5.7 g/m<sup>2</sup>&nbsp;have been administered as intravenous infusions over 30 minutes every other week, with clinically acceptable toxicity. In the event of suspected overdose, the patient should be monitored with appropriate blood counts and should receive supportive therapy as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: pyrimidine analogues</p><p>ATC code: L01BC05</p><p><strong>Cytotoxic Activity in Cell Culture Models:</strong><br />Gemcitabine exhibits significant cytotoxicity activity against a variety of cultured murine and human tumour cells. It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells through the G1/S-phase boundary.&nbsp;<em>In vitro</em>&nbsp;the cytotoxic action of gemcitabine is both concentration and time dependent.</p><p><strong>Antitumour Activity in Preclinical Models:</strong><br />In animal tumour models, the antitumour activity of gemcitabine is schedule dependent. When gemcitabine is administered daily, high animal mortality but minimal antitumoural activity is seen. If, however, gemcitabine is given every third or fourth day, it can be administered in non-lethal doses with substantial antitumoural activity against a broad spectrum of mouse tumours.</p><p><strong>Cellular Metabolism and Mechanisms of Action:</strong><br />Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolised intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic action of gemcitabine is due to inhibition of DNA synthesis by two actions of dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalysing the reactions that generate the deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP causes a reduction in the concentrations of deoxynucleosides in general, and especially in that of dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).</p><p>Likewise, a small amount of gemcitabine may also be incorporated into RNA. Thus, the reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA. DNA polymerase epsilon is essentially unable to remove gemcitabine and repair the growing DNA strands. After gemcitabine is incorporated into DNA, one additional nucleotide is added to the growing DNA strands. After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination). After incorporation into DNA, gemcitabine then appears to induce the programmed cellular death process known as apoptosis.</p><p><strong>Clinical data:</strong><br /><em>Bladder cancer:&nbsp;</em>A randomised phase III study of 405 patients with advanced or metastatic urothelial transitional cell carcinoma showed no difference between the two treatment arms, gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin (MVAC), in terms of median survival (12.8 and 14.8 months respectively, p=0.547), time to disease progression (7.4 and 7.6 months respectively, p=0.842) and response rate (49.4% and 45.7% respectively, p=0.512). However, the combination of gemcitabine and cisplatin had a better toxicity profile than MVAC.</p><p><em>Pancreatic cancer:&nbsp;</em>In a randomised phase III study of 126 patients with advanced or metastatic pancreatic cancer, gemcitabine showed a statistically significant higher clinical benefit response rate than 5-fluorouracil (23.8% and 4.8% respectively, p=0.0022). Also, a statistically significant prolongation of the time to progression from 0.9 to 2.3 months (log-rank p&lt;0.0002) and a statistically significant prolongation of median survival from 4.4 to 5.7 months (log-rank p&lt;0.0024) was observed in patients treated with gemcitabine compared to patients treated with 5-fluorouracil.</p><p><em>Non small cell lung cancer:&nbsp;</em>In a randomised phase III study of 522 patients with inoperable, locally advanced or metastatic NSCLC, gemcitabine in combination with cisplatin showed a statistically significant higher response rate than cisplatin alone (31.0% and 12.0%, respectively, p&lt;0.0001). A statistically significant prolongation of the time to progression, from 3.7 to 5.6 months (log-rank p&lt;0.0012) and a statistically significant prolongation of median survival from 7.6 months to 9.1 months (log-rank p&lt;0.004) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with cisplatin.</p><p>In another randomised phase III study of 135 patients with stage IIIB or IV NSCLC, a combination of gemcitabine and cisplatin showed a statistically significant higher response rate than a combination of cisplatin and etoposide (40.6% and 21.2%, respectively, p=0.025). A statistically significant prolongation of the time to progression, from 4.3 to 6.9 months (p=0.014) was observed in patients treated with gemcitabine/cisplatin compared to patients treated with etoposide/cisplatin.</p><p>In both studies it was found that tolerability was similar in the two treatment arms.</p><p><em>Ovarian carcinoma:&nbsp;</em>In a randomised phase III study, 356 patients with advanced epithelial ovarian carcinoma who had relapsed at least 6 months after completing platinum based therapy were randomised to therapy with gemcitabine and carboplatin (GCb), or carboplatin (Cb). A statistically significant prolongation of the time to progression of disease, from 5.8 to 8.6 months (log-rank p= 0.0038) was observed in the patients treated with GCb compared to patients treated with Cb. Differences in response rate of 47.2% in the GCb arm versus 30.9% in the Cb arm (p=0.0016) and median survival 18 months (GCb) versus 17.3 (Cb) (p=0.73) favoured the GCb arm.</p><p><em>Breast cancer:&nbsp;</em>In a randomised phase III study of 529 patients with inoperable, locally recurrent or metastatic breast cancer with relapse after adjuvant/neoadjuvant chemotherapy, gemcitabine in combination with paclitaxel showed a statistically significant prolongation of time to documented disease progression from 3.98 to 6.14 months (log-rank p=0.0002) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel. After 377 deaths, the overall survival was 18.6 months versus 15.8 months (log rank p=0.0489, HR 0.82) in patients treated with gemcitabine/paclitaxel compared to patients treated with paclitaxel and the overall response rate was 41.4% and 26.2% respectively (p= 0.0002).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of gemcitabine have been examined in 353 patients in seven studies. The 121 women and 232 men ranged in age from 29 to 79 years. Of these patients, approximately 45% had non-small cell lung cancer and 35% were diagnosed with pancreatic cancer. The following pharmacokinetic parameters were obtained for doses ranging from 500 to 2,592 mg/m<sup>2</sup>&nbsp;that were infused from 0.4 to 1.2 hours.</p><p>Peak plasma concentrations (obtained within 5 minutes of the end of the infusion) were 3.2 to 45.5 &micro;g/ml. Plasma concentrations of the parent compound following a dose of 1,000 mg/m<sup>2</sup>/30-minutes are greater than 5 &mu;g/ml for approximately 30-minutes after the end of the infusion, and greater than 0.4 &mu;g/ml for an additional hour.</p><p><strong>Distribution</strong><br />The volume of distribution of the central compartment was 12.4 l/m<sup>2</sup>&nbsp;for women and 17.5 l/m<sup>2</sup>&nbsp;for men (inter-individual variability was 91.9%). The volume of distribution of the peripheral compartment was 47.4 l/m<sup>2</sup>. The volume of the peripheral compartment was not sensitive to gender.</p><p>The plasma protein binding was considered to be negligible.</p><p><em>Half-life:</em>&nbsp;This ranged from 42 to 94 minutes depending on age and gender. For the recommended dosing schedule, gemcitabine elimination should be virtually complete within 5 to 11 hours of the start of the infusion. Gemcitabine does not accumulate when administered once weekly.</p><p><strong>Metabolism:</strong><br />Gemcitabine is rapidly metabolised by cytidine deaminase in the liver, kidney, blood, and other tissues.</p><p>Intracellular metabolism of gemcitabine produces the gemcitabine mono, di, and triphosphates (dFdCMP, dFdCDP, and dFdCTP), of which dFdCDP and dFdCTP are considered active. These intracellular metabolites have not been detected in plasma or urine.</p><p>The primary metabolite, 2&#39;-deoxy-2&#39;,2&#39;-difluorouridine (dFdU), is not active and is found in plasma and urine.</p><p><strong>Excretion:</strong><br />Systemic clearance ranged from 29.2 l/hr/m<sup>2</sup>&nbsp;to 92.2 l/hr/m<sup>2</sup>&nbsp;depending on gender and age (inter-individual variability was 52.2%). Clearance for women is approximately 25% lower than the values for men. Although rapid, clearance for both men and women appears to decrease with age. For the recommended gemcitabine dose of 1,000 mg/m<sup>2</sup>&nbsp;given as a 30 minute infusion, lower clearance values for women and men should not necessitate a decrease in the gemcitabine dose.</p><p><em>Urinary excretion:</em>&nbsp;Less than 10% is excreted as unchanged drug.</p><p><em>Renal clearance was&nbsp;</em>2 to 7 l/hr/m<sup>2</sup>.</p><p>During the week following administration, 92 to 98% of the dose of gemcitabine administered is recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces.</p><p><strong>dFdCTP Kinetics:</strong><br />This metabolite can be found in peripheral blood mononuclear cells and the information below refers to these cells.</p><p>Intracellular concentrations increase in proportion to gemcitabine doses of 35-350 mg/m<sup>2</sup>/30 min, which give steady-state concentrations of 0.4-5 &micro;g/ml. At gemcitabine plasma concentrations above 5 &micro;g/ml, dFdCTP levels do not increase, suggesting that the formation is saturable in these cells.</p><p><em>Half-life of terminal elimination</em>: 0.7-12 hours.</p><p><strong>dFdU Kinetics</strong>:<br /><em>Peak plasma concentrations (3-15 minutes after end of 30 minute infusion, 1,000 mg/m<sup>2</sup>):</em><br />28-52&micro;g/ml.</p><p><em>Trough concentration following once weekly dosing:</em><br />0.07-1.12 &micro;g/ml, with no apparent accumulation.</p><p><em>Triphasic plasma concentration versus time curve, mean half-life of terminal phase:</em><br />65 hours (range 33-84 hours).</p><p><em>Formation of dFdU from parent compound:</em><br />91%-98%.</p><p><em>&nbsp;Mean volume of distribution of central compartment:</em><br />18 l/m<sup>2</sup>&nbsp;(range 11-22 l/m<sup>2</sup>).</p><p><em>&nbsp;Mean steady-state volume of distribution (Vss):</em><br />150 l/m<sup>2</sup>&nbsp;(range 96-228 l/m<sup>2</sup>).</p><p><em>Tissue distribution:</em><br />Extensive.</p><p><em>Mean apparent clearance:</em><br />2.5 l/hr/m<sup>2</sup>&nbsp;(range 1-4 l/hr/m<sup>2</sup>).</p><p><em>Urinary excretion:</em><br />All.</p><p><em>Gemcitabine and Paclitaxel Combination Therapy:</em><br />Combination therapy did not alter the pharmacokinetics of either gemcitabine or paclitaxel.</p><p><em>Gemcitabine and Carboplatin Combination Therapy:</em><br />When given in combination with carboplatin the pharmacokinetics of gemcitabine were not altered.</p><p><strong>Renal impairment:</strong><br />Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent, significant effect on gemcitabine pharmacokinetics<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeated dose studies of up to 6 months duration in mice and dogs, the principal finding was schedule and dose-dependent haematopoetic suppression, which was reversible. Gemcitabine showed mutagenic potential in an&nbsp;<em>in-vitro</em>mutation test and in an&nbsp;<em>in-vivo</em>&nbsp;bone marrow micronucleus test. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of gemcitabine.</p><p>In fertility studies, gemcitabine caused reversible hypospermatogenesis in male mice. No effect on the fertility of females has been detected.</p><p>Evaluation of experimental animal studies has shown reproductive toxicity e.g. birth defects and other effects on the development of the embryo or foetus, the course of gestation or peri- and postnatal development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp; Sodium acetate</p><p>-&nbsp;&nbsp; Hydrochloric acid</p><p>-&nbsp;&nbsp; Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal product except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 

After reconstitution and dilution: 
Gemcitabine Jazeera solutions are stable for 24 hours at controlled room temperature (20 to 25°C). 

From a microbiological point of view, it is advised that the product is used immediately.

Discard unused portion. 

Solutions of reconstituted Gemcitabine Jazeera should not be refrigerated, as crystallization may occur. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p><p>For storage condition of the reconstituted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I clear glass vials stoppered with bromobutyl grey stoppers and sealed with aluminium flip-off caps.</p><p>Pack size: 1 Vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Reconstitution:</em></strong><br />For single use only</p><p>This medicinal product has only been shown to be compatible with 9 mg/ml (0.9%) sodium chloride solution for injection. Accordingly, only this diluent should be used for reconstitution.</p><p>Compatibility with other active substances has not been studied. Therefore, it is not recommended to mix this medicinal product with other active substances when reconstituted.</p><p>Reconstitution at concentrations greater than 38 mg/ml may result in incomplete dissolution, and should be avoided.</p><p>To reconstitute, slowly add the appropriate volume of 9 mg/ml (0.9%) sodium chloride solution for injection (as stated in the table below) and shake to dissolve.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Presentation</strong></p></td><td style="vertical-align:top; width:272px"><p><strong>Volume of 9 mg/ml (0.9%) sodium chloride&nbsp; solution for injection to be added</strong></p></td><td style="vertical-align:top; width:179px"><p><strong>Displacement volume</strong></p></td><td style="vertical-align:top"><p><strong>Final concentration</strong></p></td></tr><tr><td style="vertical-align:top"><p>200 mg</p></td><td style="vertical-align:top; width:272px"><p>5 ml</p></td><td style="vertical-align:top; width:179px"><p>0.26 ml</p></td><td style="vertical-align:top"><p>38 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>1000 mg</p></td><td style="vertical-align:top; width:272px"><p>25 ml</p></td><td style="vertical-align:top; width:179px"><p>1.3 ml</p></td><td style="vertical-align:top"><p>38 mg/ml</p></td></tr></tbody></table><p>The appropriate amount of medicinal product may be further diluted with 9 mg/ml (0.9%) sodium chloride solution for injection to a concentration as low as 0.1 mg/ml.</p><p>Parenteral medicinal products should be inspected visually for particulate matter and discolouration, prior to administration, whenever solution and container permit.</p><p>Any unused solution should be discarded as described below.</p><p><strong><em>Guidelines for the Safe Handling of Cytotoxic Medicinal Products:</em></strong><br />Local guidelines on safe preparation and handling of cytotoxic medicinal products must be adhered to. Cytotoxic preparations should not be handled by pregnant staff. The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used. This should be performed in a designated area. The work surface should be covered with disposable plastic-backed absorbent paper.</p><p>Suitable eye protection, disposable gloves, face mask and disposable apron should be worn. Precautions should be taken to avoid the medicinal product accidentally coming into contact with the eyes. If accidental contamination occurs, the eye should be washed with water thoroughly and immediately.</p><p>Syringes and infusion sets should be assembled carefully to avoid leakage (use of Luer lock fittings is recommended). Large bore needles are recommended to minimise pressure and the possible formation of aerosols. The latter may also be reduced by the use of a venting needle.</p><p>Actual spillage or leakage should be mopped up wearing protective gloves. Excreta and vomit must be handled with care.</p><p><strong><em>Disposal:</em></strong><br />Adequate care and precaution should be taken in the disposal of items used to reconstitute this medicinal product. Any unused dry product or contaminated materials should be placed in a high-risk waste bag. Sharp objects (needles, syringes, vials, etc) should be placed in a suitable rigid container. Personnel concerned with the collection and disposal of this waste should be aware of the hazard involved. Waste material should be destroyed by incineration. Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25 January 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>